Syros Pharmaceuticals

Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies

Retrieved on: 
Saturday, December 5, 2020
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Branches of biology, Leukemia, Retinoic acid receptor alpha, Acute myeloid leukemia, Acute Promyelocytic Leukemia, Syros Pharmaceuticals

Its rare to talk about cures in cancer, said Nancy Simonian, M.D., Chief Executive Officer of Syros.

Key Points: 
  • Its rare to talk about cures in cancer, said Nancy Simonian, M.D., Chief Executive Officer of Syros.
  • SY-2101 is in development for the treatment of APL, a subtype of acute myeloid leukemia (AML) defined by a fusion of the RARA and PML genes.
  • If successful, Syros believes it could file a New Drug Application (NDA) with the FDA in 2024.
  • A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .